Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Waldenstrom’s macroglublinemia

- PMLiVE

J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

EU flag

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation would allow blood cancer patients to halve their daily pill intake

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer

Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

The aggressive form of lung cancer accounts for around 15% of all cases of the disease

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth

- PMLiVE

BeiGene’s Brukinsa recommended by NICE to treat marginal zone lymphoma

Approximately 2,600 cases of the blood cancer are diagnosed in the UK every year

- PMLiVE

BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer

Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links